Human TROP2 Antibody for ADC - Sacituzumab Biosimilar

Monoclonal human IgG1 antibody against TROP2 for antibody-drug conjugation

InvivoGen provides Anti-TROP2-hIgG1, a monoclonal antibody (mAb) specifically developed for the generation of antibody-drug conjugates (ADCs). This mAb features:

• the variable region of sacituzumab, which specifically targets the human trophoblast cell-surface antigen 2 (TROP2),
• a human IgG1 constant region that displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

InvivoGen's Anti-TROP2-hIgG1 has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography. The antibody formulation contains no tris, cysteine, glycine, or any other amine or thiol function.

TROP2 background

TROP2 (trophoblast cell-surface antigen 2), also known as TACD2 (tumor-associated calcium signal transducer 2), is a transmembrane protein expressed in normal human tissues, including breast, cervix, kidney, lung, and pancreas, and is upregulated in most tumors of epithelial origin [1]. TROP2 plays an important role in embryonic development and is implicated in several oncogenetic signaling pathways leading to proliferation [1].
One therapeutic strategy aiming at killing TROP2+ cancer cells, notably in triple-negative breast cancer patients, uses the FDA-approved antibody-drug conjugate (ADC) Trodelvy [2,3]. It consists of the combination of the Anti-TROP2 sacituzumab and the SN-38 cytotoxic payload [2,3]. This ADC allows targeted drug delivery to cancer cells in addition to the mAb-mediated effector functions [2,3]. Other TROP2-targeting ADCs featuring different cytotoxic cargos have been developed and have progressed to human clinical trials [4].

In a co-culture of TROP2+ tumor cells and human peripheral blood monocytes (PBMCs), ADCs combining InvivoGen's Anti-TROP2-hIgG1 and STING or TLR7 agonists induce a significantly higher production of IL-6 and CXCL10 pro-inflammatory cytokines than unconjugated agonists or negative control ADCs (see Figures).

Key features of Anti-TROP2-hIgG1

• Clinically-relevant variable region targeting human TROP2 (sacituzumab)
• Human IgG1 constant region for high effector functions
• Functionally validated by flow cytometry and ADC-based cellular assays
• The absence of bacterial contamination has been confirmed

InvivoGen offers conjugatable PRR ligands for building immunostimulatory Anti-TROP2 ADCs.
You may choose from TLR7 and STING agonists:
- Conjugatable TLR7 agonists: TL7-887 and TL7-975
- Conjugatable STING agonists: STG-982 and STG-968

Learn more about bioconjugation

References

1. Trerotola, M., et al., 2013. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32, 222–233.
2. Drago J.Z. et al., 2021. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 18-6):327.
3. Tarantino P. et al., 2022. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 72:165-182.
4. Shaffer, C. 2021. Trop2 deal heats up antibody–drug conjugate space in cancer. Nat Biotechnol 39, 128–130.